Growth Equity
Gyrus Capital
Gyrus Capital takes minority stakes in growing companies, usually without full control, from Geneva, Switzerland. It states a focus on healthcare & life sciences and business & professional services.
Stated investment criteria
What Gyrus Capital says it buys
Read from Gyrus Capital’s own website in August 2026. This is what the firm says it buys, not what anyone has recorded it buying, and figures are shown in the currency the firm itself used - nothing here is converted. Every line links to the page it was read from.
A stated mandate is a firm’s description of itself and was true of the page on the day it was read; firms widen and narrow what they will look at without updating the site. Gyrus Capital states that it will take either a controlling or a minority stake. Nothing here is a commitment by Gyrus Capital to consider any particular business, and nothing on this page is represented as being for sale.
Regulatory record
How Gyrus Capital is registered
From this firm's Form ADV, the annual filing every registered and exempt investment adviser makes to the SEC.
| Adviser status | Exempt reporting adviser |
| Regulatory assets under management | Not reported by an ERA |
| Private funds advised | 6 · $976m gross |
| SEC adviser number | CRD 334695 |
An exempt reporting adviser is not required to report regulatory assets under management, so the blank above means the question was not asked rather than that the answer is unknown. Where a figure exists it is the gross asset value of the private funds the firm advises, which is a different and usually larger measure.
Portfolio
Disclosed holdings
Companies Gyrus Capital lists on its own website. No investment years are published.
| Company | Invested | Years held | Recorded transaction |
|---|---|---|---|
| ACBC | — | — | — |
| Corcym | — | — | — |
| Corcym Case Study | — | — | — |
| Dss Case Study | — | — | — |
| Essential Pharma | — | — | — |
| Essential Pharmas Case Study | — | — | — |
| Intellera | — | — | — |
| Intellera Case Study | — | — | — |
| Neo Medical | — | — | — |
| dss+ | — | — | — |
Compiled from Gyrus Capital’s published portfolio page. Where a recorded transaction is shown, that company was the target of a reported deal and has most likely already been realised. Nothing here is represented as being for sale.
Valuation context
Transaction values in Healthcare & Life Sciences
What companies have actually sold for in healthcare & life sciences, across 1,263 recorded transactions.
The full healthcare & life sciences picture - most active acquirers, recent transactions and every investor in the sector.
For owners
Own a healthcare & life sciences business?
The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.
Request a confidential valuationFor investors
Is this Gyrus Capital?
Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.
Claim or correct this profileTargeted buyer search
Which hundred of these would actually buy your business?
A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.
Comparable investors
Similar mandates
Other growth equity investors active in healthcare & life sciences.